The regulatory role of IL-37 and IL-38 in CAR-T associated cytokine release syndrome in multiple myeloma - Takeaways - MDSpire

The regulatory role of IL-37 and IL-38 in CAR-T associated cytokine release syndrome in multiple myeloma

  • By

  • Xiujuan Huang

  • Hailong Yan

  • Jiaojiao Bai

  • Shisan Bao

  • Yi Wang

  • Qiuying Gao

  • July 14, 2026

Share

  • 1

    Multiple myeloma is characterized by malignant plasma cell proliferation and a profoundly immunosuppressive tumor microenvironment.

  • 2

    CAR-T therapy targeting BCMA has shown deep responses in relapsed/refractory multiple myeloma but is limited by cytokine release syndrome (CRS).

  • 3

    Cytokine release syndrome is a hyperinflammatory process driven by CAR-T-derived cytokines and monocyte/macrophage activation.

  • 4

    IL-37 and IL-38 are emerging as anti-inflammatory regulators that may modulate CAR-T-associated hyperinflammation.

  • 5

    Leveraging IL-37 and IL-38 could improve the safety and efficacy of CAR-T therapies in multiple myeloma.

Original Source(s)

The regulatory role of IL-37 and IL-38 in CAR-T associated cytokine release syndrome in multiple myeloma

  • by Xiujuan Huang, Hailong Yan, Jiaojiao Bai, Shisan Bao, Yi Wang, Qiuying Gao

  • July 14, 2026

Related Content

Global research landscape and trends of single-cell sequencing in sexually transmitted infections: a comprehensive bibliometric analysis from 2015 to 2025

From Peak Performance to Precision Healthcare

Travis Nemkov and Angelo D’Alessandro discuss how molecular profiling in elite athletes could inform personalized exercise, healthy aging, and cancer recovery

Editorial: Molecular pathways and signaling molecules in cancer therapy: advances and innovations